Key facts
- Adipo Therapeutics’s last known valuation is $27.0M (Feb 2026).
- It has raised $14.8M across 2 recorded rounds; the latest was Seed Round ($4.7M) in Nov 2024.
- Notable investors include Elevate Ventures, AJI Capital, David Campbell, IU Ventures, John Lechleiter — 13 tracked in total.
- Adipo Therapeutics has filed 2 Form Ds with the SEC since 2020, most recently Dec 2024 ($4.7M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Adipo Therapeutics
Funding rounds
2 roundsAbout Adipo Therapeutics
Developer of polymer-based nanoparticles designed to transform the treatment of obesity-related diseases. The company's notch-inhibiting nanoparticles are weekly, self-injected directly into subcutaneous white adipose tissue to convert energy-storing white fat into energy-burning brown fat, leading to systemic metabolic changes including increased energy expenditure, decreased body weight, improved insulin sensitivity, and improved fat storage, enabling patients to lose body weight naturally and restoring metabolic balance for people living with diabetes.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2016
- Employees
- 9
- Website
- adipotherapeutics.com/
- Ownership
- Privately Held (backing)
Adipo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adipo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adipo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.